Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
Hermine I BrunnerPierre QuartierEkaterina AlexeevaTamàs ConstantinIsabelle Kone-PautKatherine MarzanRayfel SchneiderNico M WulffraatVyacheslav ChasnykIrit TiroshTilmann KallinichJasmin Kuemmerle-DeschnerCarine WoutersBernard LauwerysIrina NikishinaMaria TrachanaOlga VougioukaAlberto MartiniDaniel J LovellJeremy LevyEleni VritzaliNicolino Rupertonull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Canakinumab provided rapid and sustained improvement of active systemic JIA irrespective of the presence of fever at treatment initiation.